Long-term survival analysis of ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma conforming to the Milan criteria: primary versus recurrent HCC

References

• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1–10. doi: 10.1016/S0140-6736(18)30010-2.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
   PubMed Web of Science ®Google Scholar
• Xie DY, Ren ZG, Zhou J, et al. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9(4):452–463. doi: 10.21037/hbsn-20-480.
   PubMed Web of Science ®Google Scholar
• Wang Z, Liu M, Zhang DZ, et al. Microwave ablation versus laparoscopic resection as first-line therapy for solitary 3-5-cm HCC. Hepatology. 2022;76(1):66–77. doi: 10.1002/hep.32323.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Yang Y, Zhou B, et al. Challenges facing percutaneous ablation in the treatment of hepatocellular carcinoma: extension of ablation criteria. J Hepatocell Carcinoma. 2021;8:625–644. doi: 10.2147/JHC.S298709.
   PubMed Web of Science ®Google Scholar
• Xu Y, Shen Q, Wang N, et al. Percutaneous microwave ablation of 5-6 cm unresectable hepatocellular carcinoma: local efficacy and long-term outcomes. Int J Hyperthermia. 2017;33(3):247–254. doi: 10.1080/02656736.2016.1239842.
   PubMed Web of Science ®Google Scholar
• Cucchetti A, Elshaarawy O, Han G, et al. Potentially curative therapies’ for hepatocellular carcinoma: how many patients can actually be cured? Br J Cancer. 2023;128(9):1665–1671. doi: 10.1038/s41416-023-02188-z.
   PubMed Web of Science ®Google Scholar
• Cheung TT, Ma KW, She WH. A review on radiofrequency, microwave and high-intensity focused ultrasound ablations for hepatocellular carcinoma with cirrhosis. Hepatobiliary Surg Nutr. 2021;10(2):193–209. doi: 10.21037/hbsn.2020.03.11.
   PubMed Web of Science ®Google Scholar
• Nault JC, Sutter O, Nahon P, et al. Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations. J Hepatol. 2018;68(4):783–797. doi: 10.1016/j.jhep.2017.10.004.
   PubMed Web of Science ®Google Scholar
• Famularo S, Donadon M, Cipriani F, et al. Curative versus palliative treatments for recurrent hepatocellular carcinoma: a multicentric weighted comparison. HPB (Oxford). 2021;23(6):889–898. doi: 10.1016/j.hpb.2020.10.007.
   PubMed Web of Science ®Google Scholar
• Tampaki M, Papatheodoridis GV, Cholongitas E. Intrahepatic recurrence of hepatocellular carcinoma after resection: an update. Clin J Gastroenterol. 2021;14(3):699–713. doi: 10.1007/s12328-021-01394-7.
   PubMed Web of Science ®Google Scholar
• Tabrizian P, Jibara G, Shrager B, et al. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2015;261(5):947–955. doi: 10.1097/SLA.0000000000000710.
   PubMed Web of Science ®Google Scholar
• Papaconstantinou D, Tsilimigras DI, Pawlik TM. Recurrent hepatocellular carcinoma: patterns, detection, staging and treatment. J Hepatocell Carcinoma. 2022;9:947–957. doi: 10.2147/JHC.S342266.
   PubMed Web of Science ®Google Scholar
• Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–853. doi: 10.1053/j.gastro.2015.12.041.
   PubMed Web of Science ®Google Scholar
• Yin X, Hua T, Liang C, et al. Efficacy of re-resection versus radiofrequency ablation for recurrent Barcelona Clinic Liver Cancer stage 0/a hepatocellular carcinoma (HCC) after resection for primary HCC. Transl Cancer Res. 2019;8(4):1035–1045. doi: 10.21037/tcr.2019.06.11.
   PubMed Web of Science ®Google Scholar
• Song KD, Lim HK, Rhim H, et al. Repeated hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma after hepatic resection: a propensity score matching study. Radiology. 2015;275(2):599–608. doi: 10.1148/radiol.14141568.
   PubMed Web of Science ®Google Scholar
• Sun WC, Chen IS, Liang HL, et al. Comparison of repeated surgical resection and radiofrequency ablation for small recurrent hepatocellular carcinoma after primary resection. Oncotarget. 2017;8(61):104571–104581. doi: 10.18632/oncotarget.21604.
   PubMedGoogle Scholar
• Bai XM, Cui M, Yang W, et al. The 10-year survival analysis of radiofrequency ablation for solitary hepatocellular carcinoma 5 cm or smaller: primary versus recurrent HCC. Radiology. 2021;300(2):458–469. doi: 10.1148/radiol.2021200153.
   PubMed Web of Science ®Google Scholar
• Zhang TT, Luo HC, Cui X, et al. Ultrasound-guided percutaneous microwave ablation treatment of initial recurrent hepatocellular carcinoma after hepatic resection: long-term outcomes. Ultrasound Med Biol. 2015;41(9):2391–2399. doi: 10.1016/j.ultrasmedbio.2015.04.019.
   PubMed Web of Science ®Google Scholar
• Lee SK, Chung DJ, Cho SH. A real-world comparative study of microwave and radiofrequency ablation in treatment-naive and recurrent hepatocellular carcinoma. J Clin Med. 2022;11(2):302.
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Del Prete V, Antonino M, et al. Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation. Dig Liver Dis. 2014;46(11):1014–1019. doi: 10.1016/j.dld.2014.07.012.
   PubMedGoogle Scholar
• Ho CM, Lee CH, Lee MC, et al. Survival after treatable hepatocellular carcinoma recurrence in liver recipients: a nationwide cohort analysis. Front Oncol. 2020;10:616094. doi: 10.3389/fonc.2020.616094.
   PubMed Web of Science ®Google Scholar
• Wei T, Zhang XF, Bagante F, et al. Early versus late recurrence of hepatocellular carcinoma after surgical resection based on post-recurrence survival: an international multi-institutional analysis. J Gastrointest Surg. 2021;25(1):125–133. doi: 10.1007/s11605-020-04553-2.
   PubMed Web of Science ®Google Scholar
• Saito R, Amemiya H, Hosomura N, et al. Prognostic factors for post-recurrent survival in hepatocellular carcinoma after curative resection. Anticancer Res. 2019;39(6):3033–3038. doi: 10.21873/anticanres.13436.
   PubMed Web of Science ®Google Scholar
• Wang WQ, Lv X, Li J, et al. Repeat hepatectomy versus microwave ablation for solitary and small (</=3 cm) recurrent hepatocellular carcinoma with early or late recurrence: a propensity score matched study. Eur J Surg Oncol. 2022;49(5):1001–1008. doi: 10.1016/j.ejso.2022.12.016.
   PubMed Web of Science ®Google Scholar
• Hu H, Chi JC, Liu R, et al. Microwave ablation for peribiliary hepatocellular carcinoma: propensity score analyses of long-term outcomes. Int J Hyperthermia. 2021;38(1):191–201. doi: 10.1080/02656736.2019.1706766.
   PubMed Web of Science ®Google Scholar
• Liu W, Zheng Y, He W, et al. Microwave vs radiofrequency ablation for hepatocellular carcinoma within the milan criteria: a propensity score analysis. Aliment Pharmacol Ther. 2018;48(6):671–681. doi: 10.1111/apt.14929.
   PubMed Web of Science ®Google Scholar
• Kuroda H, Nagasawa T, Fujiwara Y, et al. Comparing the safety and efficacy of microwave ablation using thermosphere (TM) technology versus radiofrequency ablation for hepatocellular carcinoma: a propensity score-matched analysis. Cancers (Basel). 2021;13(6):1295. doi: 10.3390/cancers13061295.
   PubMed Web of Science ®Google Scholar
• Chu HH, Kim JH, Kim PN, et al. Surgical resection versus radiofrequency ablation very early-stage HCC (</=2 cm single HCC): a propensity score analysis. Liver Int. 2019;39(12):2397–2407. doi: 10.1111/liv.14258.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–558. doi: 10.1200/JCO.2014.57.9151.
   PubMed Web of Science ®Google Scholar
• Teng W, Liu KW, Lin CC, et al. Insufficient ablative margin determined by early computed tomography may predict the recurrence of hepatocellular carcinoma after radiofrequency ablation. Liver Cancer. 2015;4(1):26–38. doi: 10.1159/000343877.
   PubMed Web of Science ®Google Scholar
• Joliat GR, Allemann P, Labgaa I, et al. Treatment and outcomes of recurrent hepatocellular carcinomas. Langenbecks Arch Surg. 2017;402(5):737–744. doi: 10.1007/s00423-017-1582-9.
   PubMed Web of Science ®Google Scholar
• Ryu T, Takami Y, Wada Y, et al. Efficacy of surgical microwave ablation for recurrent hepatocellular carcinoma after curative hepatectomy. HPB (Oxford). 2020;22(3):461–469. doi: 10.1016/j.hpb.2019.08.001.
   PubMed Web of Science ®Google Scholar
• Gupta S, Khan S, Kawka M, et al. Clinical utility of clonal origin determination in managing recurrent hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2021;15(10):1159–1167. doi: 10.1080/17474124.2021.1967144.
   PubMed Web of Science ®Google Scholar
• Galle PR, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39(12):2214–2229. doi: 10.1111/liv.14223.
   PubMed Web of Science ®Google Scholar
• Liu PH, Hsu CY, Hsia CY, et al. ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD era. J Gastroenterol Hepatol. 2017;32(4):879–886. doi: 10.1111/jgh.13608.
   PubMed Web of Science ®Google Scholar
• Chong CC, Chan AW, Wong J, et al. Albumin-bilirubin grade predicts the outcomes of liver resection versus radiofrequency ablation for very early/early stage of hepatocellular carcinoma. Surgeon. 2018;16(3):163–170. doi: 10.1016/j.surge.2017.07.003.
   PubMed Web of Science ®Google Scholar
• He W, Peng B, Tang Y, et al. Nomogram to predict survival of patients with recurrence of hepatocellular carcinoma after surgery. Clin Gastroenterol Hepatol. 2018;16(5):756–764 e10. doi: 10.1016/j.cgh.2017.12.002.
   PubMed Web of Science ®Google Scholar
• Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg. 2019;154(3):209–217. doi: 10.1001/jamasurg.2018.4334.
   PubMed Web of Science ®Google Scholar
• Qi C, Li S, Zhang L. Development and validation of a clinicopathological-based nomogram to predict the survival outcome of patients with recurrent hepatocellular carcinoma after hepatectomy who underwent microwave ablation. Cancer Manag Res. 2020;12:7589–7600. doi: 10.2147/CMAR.S266052.
   PubMed Web of Science ®Google Scholar
• Long H, Zhou X, Zhang X, et al. 3D fusion is superior to 2D point-to-point contrast-enhanced US to evaluate the ablative margin after RFA for hepatocellular carcinoma. Eur Radiol. 2023;34(2):1247–1257. doi: 10.1007/s00330-023-10023-5.
   PubMed Web of Science ®Google Scholar
• Laimer G, Schullian P, Jaschke N, et al. Minimal ablative margin (MAM) assessment with image fusion: an independent predictor for local tumor progression in hepatocellular carcinoma after stereotactic radiofrequency ablation. Eur Radiol. 2020;30(5):2463–2472. doi: 10.1007/s00330-019-06609-7.
   PubMed Web of Science ®Google Scholar
• Solbiati M, Muglia R, Goldberg SN, et al. A novel software platform for volumetric assessment of ablation completeness. Int J Hyperthermia. 2019;36(1):337–343.
   PubMed Web of Science ®Google Scholar